Ajai Chari, MD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Specialties:Cancer (Oncology), Hematology-Oncology
Dr Chari is an Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office. Clinical Interests: Plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). Dr Chari has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. Research Interests: Dr Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials as well as the national and international PI of several industry sponsored studies. As the Director of Clinical Research in the Multiple Myeloma Program, he oversees a program renowned nationally not only for high volume patient accruals but also rigorous quality assurance. The program has played a pivotal role in the approval of each of the 5 most recent drugs to be approved by the FDA for the treatment of multiple myeloma.
- AL Amyloidosis
- Bone Marrow Transplantation
- Bone Marrow Transplantation, Autologous
- Clinical Trials
- Hematologic Malignancies
- Multiple Myeloma
- Plasma Cell Neoplasms
- Waldenström's Macroglobulinemia
MD, UCLA School of Medicine
Residency, Internal Medicine, Columbia University Medical Center
Fellowship, Hematology & Onc., University of California - San Francisco
Health Care Provider of the Year, Leukemia Lymphoma Society
Ewig Teaching Award, Deparatment of Medicine, Columbia University College of Physicians and Surgeons
Phi Beta Kappa, Stanford University
Best Junior Faculty Teacher Award, selected by 2008 Internal Medicine residency class, Columbia University College of Physicians and Surgeons
New York Metro Super Doctors 2011-2015
- An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple Myeloma
The purpose of this study is to see if subcutaneous (SC) daratumumab is safe, well tolerated and to find out how long SC daratumumab remains in and acts on the body. The purpose of this study is to also find out how your body responds to daratumumab after a SC or IV infu...
- A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test what doses of GSK2110183 can be given safely in combination with bortezomib and dexamethasone. Bortezomib (also known as Velcade) is a type of medicine called a proteasome inhibitor and is approved to treat multiple myeloma and certain type...
- An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data. Daratumumab is not approved for use by the U.S. Food and Drug Administration (FDA) or any Regulatory Authority in the European Economic Area (EEA), Eastern...
- Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to look at what happens (both good and bad) when daratumumab (the experimental medication used in this study which is also known as JNJ-54767414) is given with two other drugs called lenalidomide and dexamethasone compared to just giving those two ...
- A Phase 1b Study of SAR65098 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
The purpose of this study is to test the safety of SAR650984 with carfilzomib at different dose levels. We want to find out what effects, good and/or bad, the combination has on you and your myeloma. SAR650984 is an antibody directed against CD38, a receptor antige...
- A Multicenter Phase 1/2b of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
Ibrutinib is a type of drug called a “kinase inhibitor”. “Kinases” are proteins inside cells that help cells live and grow. The specific kinase inhibited or “blocked” by ibrutinib is believed to help blood cancer cells live and grow. By inhibiting the activity of this specific...
- A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
The purpose of this study is to find the dose of the experimental drug, daratumumab, that would be best to use in future studies for the treatment of Smoldering Multiple Myeloma (SMM). The effects of SMM as well as any side effects will be explored.
- A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
ARRY-520 is an experimental drug that has not been approved by the Food and Drug Administratio...
- A Phase II , Single-Center, Open Label study of Oral Panobinostat (LBH589) when administered in combination with Lenalidomide and weekly Dexamethasone in patients with multiple myeloma
The study drug, panobinostat (LBH589), is made by Novartis Pharmaceuticals Corporation. Panobinostat has not yet been approv...
- A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor, with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
This study is being done to learn more about a combination of 3 drugs called Selinexor, carfilzomib, and dexamethasone given to persons with multiple myeloma who have gotten worse and are not responding to the standard drugs for multiple myeloma, like bortezomib (Velcade), tha...
- A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma is a cancer of the blood that is currently incurable- so, even treatments that work may stop working after some time. The purpose of this study is to determine the safety and activity of a drug known as pomalidomide in combination with two other commerci...
- An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
Genetic research can help scientists understand how drugs work and what causes diseases. Janssen Research & Development LLC (the sponsor) would like to collect an extra blood ...
- A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
The experimental drug used in this study is called Daratumumab or JNJ-54767414. The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination Lenalido...
- An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma
The experimental drug used in this study is called HuMax CD38 monoclonal antibody, (also referred to as daratumumab or JNJ-54767414). Daratumumab is being tested together with various drug combinations that are standard treatments for Multiple Myeloma.
- An Open-label, Multicenter Rollover Study to Allow Continued Access to Filanesib (ARRY-520) for Patients with Multiple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored by Array BioPharma Inc.
You may qualify to take part in this research study because you were previously enrolled on a Filanesib study at the Mount Sinai Medical Center. The "parent study" you now participate in (GCO # 10-1383) will be closing and therefore Filanesib will be longer available to ...
- Phase I/Ib Pharmacokinetics Study of Oral MLN9708 Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients with Normal Renal Function or Severe Renal Impairment
The purpose of this study is to assess the effect of MLN9708 on pharmacokinetics (which is how the body processes a drug) and safety in Multiple Myeloma patients with severe renal insufficiency versus those with normal renal function.
The use of MLN9708 in this study...
Chari A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics : targets & therapy 2010; 4.
Barley K, Harris JA, Diefenbach C, Jagannath S, Chari A. Misdiagnosis of non-hodgkin lymphoma as multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Dec; 30(35).
Chari A, Barley K, Jagannath S, Osman K. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clinical lymphoma, myeloma & leukemia 2013 Feb; 13(1).
Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clinical advances in hematology & oncology : H&O 2013 Aug; 11(8).
Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies. Clinical advances in hematology & oncology : H&O 2013; 11(9).
Biran N, Ely S, Chari A. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Current hematologic malignancy reports 2014 Dec; 9(4).
Chari A. Novel Targets in Multiple Myeloma. American Journal of Hematology/Oncology 2015 March ; 11(3): 11-16.